Platelet Findings, Coagulation Pathways, PT/aPTT, and Hemostasis Testing

Hemostasis Logic for the MLT Bench

The ASCP MLT outline lists Hemostasis under Hematology and includes coagulation pathways, fibrinolysis, the vascular system, coagulation factor deficiencies, DIC, PT/INR, aPTT, fibrinogen, D-dimer, thrombin time, mixing studies, platelet function testing, hypercoagulability assessment, and anti-Xa. The MLT does not need to manage the patient, but must understand which part of hemostasis each test evaluates and when a result pattern is suspicious.

Primary versus secondary hemostasis

Primary hemostasis starts with vascular injury, platelet adhesion, activation, and aggregation. Problems usually cause mucocutaneous bleeding such as petechiae, purpura, epistaxis, gum bleeding, or menorrhagia. Platelet count, smear estimate, platelet morphology, and platelet function tests belong here.

Secondary hemostasis stabilizes the platelet plug with fibrin. Problems more often cause deep tissue bleeding, hemarthroses, large hematomas, or delayed bleeding after procedures. PT/INR, aPTT, fibrinogen, thrombin time, and factor assays belong here.

Platelet count and morphology

ASCP's exam-purpose platelet reference range is 150-450 x 10^3/uL. A low platelet count can be real or spurious. Always consider clots, platelet clumps, giant platelets, platelet satellitism, and instrument flags. EDTA-dependent platelet clumping can falsely lower the automated count; the smear may show clumps at the feather edge or throughout the film. The appropriate response is to follow SOP for recollection or alternate anticoagulant confirmation, not to treat the number as automatically true.

Platelet morphology also gives clues. Giant platelets can appear when marrow is releasing young platelets or in inherited platelet disorders. Bernard-Soulier syndrome classically has thrombocytopenia with giant platelets and defective adhesion. Glanzmann thrombasthenia has defective aggregation with a platelet count that may be normal. von Willebrand disease is a primary hemostasis disorder because defective vWF impairs platelet adhesion and can also reduce factor VIII stability.

Pathway screen table

PT/INR is most associated with the extrinsic and common pathways: factors VII, X, V, II, and fibrinogen. The INR standardizes PT for warfarin monitoring. aPTT is most associated with intrinsic and common pathways: factors XII, XI, IX, VIII, X, V, II, and fibrinogen. Anti-Xa testing is used for heparin or selected anticoagulant monitoring depending on method and policy.

Mixing studies at a high level

A mixing study combines patient plasma with normal plasma, often in a 1:1 mix. If the prolonged clotting time corrects, normal plasma supplied the missing factor activity, so a factor deficiency pattern is likely. If it does not correct, an inhibitor pattern is likely. Some inhibitors are immediate; others are time- and temperature-dependent, so labs may evaluate immediate and incubated results.

For MLT exam purposes, keep the interpretation high level unless the stem gives more detail. Corrects means deficiency pattern. Fails to correct means inhibitor pattern such as lupus anticoagulant or a specific factor inhibitor. Lupus anticoagulant can prolong phospholipid-dependent clotting assays in vitro but is associated clinically with thrombosis risk, not simple bleeding.

DIC and fibrinolysis pattern

Disseminated intravascular coagulation is a consumptive process. The classic lab cluster is thrombocytopenia, prolonged PT, prolonged aPTT, low fibrinogen, elevated D-dimer, and schistocytes on smear. Not every patient has every finding at one time, but the pattern is much stronger than any single result.

Coagulation specimen quality

Coagulation testing depends on a correct sodium citrate ratio. Standard light-blue tubes use a 9:1 blood-to-anticoagulant ratio. Underfilling leaves excess citrate, binds too much calcium during testing, and can falsely prolong clotting times. Markedly high hematocrit, commonly above 55%, requires citrate adjustment because plasma volume is reduced. Clotted blue-top specimens are unacceptable for routine clot-based testing. Heparin contamination from a line draw and EDTA carryover from wrong order of draw can also prolong results.

Before interpreting a strange PT/aPTT pattern, the MLT should check specimen fill, clot status, collection source, anticoagulant exposure, instrument flags, QC status, and delta history. A technically bad specimen should not be explained as a rare factor deficiency.